Core Viewpoint - The company, Celery Medical (603716.SH), plans to increase its investment in its subsidiary, Wuhan Huajiyuan Biotechnology Development Co., Ltd., by 42.74 million yuan, which will raise its ownership stake to 41% [1] Group 1: Investment Details - The actual controller, Wen Wei, intends to acquire a 10% stake from shareholder Sun Danping for 27.2 million yuan, based on a post-investment valuation of 272 million yuan [1] - The total investment from the company and Wen Wei will amount to 69.94 million yuan [1] Group 2: Future Plans - The target company is expected to be included in the company's consolidated financial statements as a controlled subsidiary by 2026 [1] - All parties have agreed to actively promote the clinical trials for the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project, aiming to complete Phase I and Phase IIa clinical trials within two years, followed by the implementation of Phase IIb clinical trials [1]